28.02.2013 - Belgian Gimv launches a new Healthcare and Medtech fund to invest in the European health and care sectors.
The European investment company, which manages investments of 1.8bn in 85 portfolio companies, will initially invest €50m in the new fund. The Flemish Government will also contribute €50m through Gimv's reference shareholder, VPM. The fund is seeking to attract additional investments from institutional investors.
A formal first closing is planned in the coming year, said the investment company.Over the next six years, the fund aims to invest in 10 to 15 healthcare and medtech companies in the Benelux, Germany and France. The amount per investment can peak to €25m, both in equity and quasi-equity. With a term of 12 years, the fund presents itself as a long-term partner for the projects in which it will invest. The Gimv Health & Care team will be responsible for the management of the fund.
”The ageing population, a rising number of chronic diseases and better informed patients continue to push up healthcare demand and costs“ commented Urbain Vandeurzen, Chairman of the Gimv Board of Directors ”With the new fund, we want to encourage innovative companies and service providers in the sector to respond to this."
The Health & Care fund is not Gimv's first project in this field. The Flemish Government's venture capital fund for biotech companies, Biotech Fonds Vlaanderen, is managed by Gimv. Gimv is also responsible for the management of two infrastructure funds (DG Infra+ and DG Infra Yield). In early 2009, Gimv established the Gimv-XL fund for investments in larger Flemish growth companies. Later that year, the Gimv-Agri+ Investment Fund was launched in cooperation with the famers' league Boerenbond. Lastly, in 2011, the Gimv Arkiv Tech Fund II was set up as part of the second ARKimedes arrangement.
28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.
20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck.
13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.
09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.